BRPI1016132B8 - composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável - Google Patents
composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estávelInfo
- Publication number
- BRPI1016132B8 BRPI1016132B8 BRPI1016132A BRPI1016132A BRPI1016132B8 BR PI1016132 B8 BRPI1016132 B8 BR PI1016132B8 BR PI1016132 A BRPI1016132 A BR PI1016132A BR PI1016132 A BRPI1016132 A BR PI1016132A BR PI1016132 B8 BRPI1016132 B8 BR PI1016132B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulation
- composition
- obtaining
- stable
- stable pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical class OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16579409P | 2009-04-01 | 2009-04-01 | |
| US61/165794 | 2009-04-01 | ||
| PCT/PT2010/000015 WO2010114405A2 (en) | 2009-04-01 | 2010-03-31 | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1016132A2 BRPI1016132A2 (pt) | 2016-04-19 |
| BRPI1016132B1 BRPI1016132B1 (pt) | 2020-11-24 |
| BRPI1016132B8 true BRPI1016132B8 (pt) | 2021-05-25 |
Family
ID=42229943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016132A BRPI1016132B8 (pt) | 2009-04-01 | 2010-03-31 | composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100256194A1 (enExample) |
| EP (1) | EP2413913B1 (enExample) |
| JP (2) | JP5864410B2 (enExample) |
| KR (1) | KR101824257B1 (enExample) |
| CN (2) | CN102438595B (enExample) |
| AU (1) | AU2010231962B2 (enExample) |
| BR (1) | BRPI1016132B8 (enExample) |
| CA (1) | CA2757418C (enExample) |
| DK (1) | DK2413913T3 (enExample) |
| ES (1) | ES2915698T3 (enExample) |
| MX (1) | MX361618B (enExample) |
| PL (1) | PL2413913T3 (enExample) |
| PT (1) | PT2413913T (enExample) |
| RU (1) | RU2550133C2 (enExample) |
| WO (1) | WO2010114405A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0613859B8 (pt) | 2005-07-26 | 2021-05-25 | Bial Portela & Ca Sa | inibidores da comt, seus usos, e composição farmacêutica |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| SI2481410T1 (sl) | 2007-01-31 | 2017-01-31 | Bial - Portela & Ca., S.A. | Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom |
| TW200942531A (en) | 2008-03-17 | 2009-10-16 | Bial Portela & Companhia S A | Crystal forms of a nitrocatechol |
| RU2701731C2 (ru) * | 2009-04-01 | 2019-10-01 | Биал-Портела Энд Ка, С.А. | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| EP2791134B1 (en) | 2011-12-13 | 2019-09-25 | BIAL - Portela & Cª S.A. | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| WO2019123066A1 (en) * | 2017-12-18 | 2019-06-27 | Unichem Laboratories Ltd | Process for the preparation of opicapone and intermediates thereof |
| FI3758708T3 (fi) * | 2018-03-01 | 2025-02-18 | Astrazeneca Ab | (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia |
| KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| US12097193B2 (en) | 2018-10-05 | 2024-09-24 | Bial—Portela & Ca, S.A. | Methods for the administration of COMT inhibitors |
| EP3860602A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| BR112022017401A2 (pt) | 2020-03-13 | 2022-10-18 | Bial Portela & Ca Sa | Opicapona micronizada |
| GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
| GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| EP4262798A1 (en) | 2020-12-17 | 2023-10-25 | Bial-Portela & CA, S.A. | Treatment regimens for early idiopathic parkinson's disease |
| US20240300930A1 (en) * | 2021-02-26 | 2024-09-12 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
| GB202212082D0 (en) | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| IL321931A (en) | 2023-01-06 | 2025-09-01 | Insmed Inc | New and reversible DPP1 inhibitors and their uses |
| AU2023449890A1 (en) | 2023-05-25 | 2025-11-27 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) * | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4085563A (en) * | 1977-01-31 | 1978-04-25 | Campbell Soup Company | Cookie dispensing apparatus |
| US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4368668A (en) * | 1981-05-15 | 1983-01-18 | Veb Kombinat Polygraph "Werner Lamberz" Leipzig | Printing plate mounting arrangement |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| US6361794B1 (en) * | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| US6206110B1 (en) * | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| AU762245B2 (en) * | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| GB2344819A (en) * | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| ATE445701T1 (de) * | 2000-11-28 | 2009-10-15 | Zymogenetics L L C | Zytokine rezeptor zcytor19 |
| US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| US7867516B2 (en) * | 2001-01-29 | 2011-01-11 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
| AU2002313633B2 (en) * | 2001-06-08 | 2007-03-01 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
| CN100364531C (zh) * | 2002-12-18 | 2008-01-30 | 西托维亚公司 | 3,5－二取代－[1,2,4]－二唑及类似物和其用途 |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| ES2933479T3 (es) * | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Estabilidad mejorada de formulaciones de progestágenos |
| US7300406B2 (en) * | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| DE602005020611D1 (de) * | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| EP1625849A1 (en) * | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20080051441A1 (en) * | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| US20060257473A1 (en) * | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| ES2371774T3 (es) * | 2005-06-03 | 2012-01-10 | Abbott Laboratories | Derivados de ciclobutilamina. |
| JP2007024970A (ja) * | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| BRPI0613859B8 (pt) * | 2005-07-26 | 2021-05-25 | Bial Portela & Ca Sa | inibidores da comt, seus usos, e composição farmacêutica |
| US20070048384A1 (en) * | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| JP2008162955A (ja) * | 2006-12-28 | 2008-07-17 | Chugai Pharmaceut Co Ltd | バリン含有高密度顆粒剤 |
| SI2481410T1 (sl) * | 2007-01-31 | 2017-01-31 | Bial - Portela & Ca., S.A. | Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom |
| PE20081891A1 (es) * | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
| TW200942531A (en) * | 2008-03-17 | 2009-10-16 | Bial Portela & Companhia S A | Crystal forms of a nitrocatechol |
-
2010
- 2010-03-31 US US12/750,957 patent/US20100256194A1/en not_active Abandoned
- 2010-03-31 CA CA2757418A patent/CA2757418C/en active Active
- 2010-03-31 JP JP2012503351A patent/JP5864410B2/ja active Active
- 2010-03-31 RU RU2011143619/15A patent/RU2550133C2/ru active IP Right Revival
- 2010-03-31 KR KR1020117025867A patent/KR101824257B1/ko active Active
- 2010-03-31 CN CN201080022455.3A patent/CN102438595B/zh active Active
- 2010-03-31 AU AU2010231962A patent/AU2010231962B2/en active Active
- 2010-03-31 ES ES10714386T patent/ES2915698T3/es active Active
- 2010-03-31 WO PCT/PT2010/000015 patent/WO2010114405A2/en not_active Ceased
- 2010-03-31 BR BRPI1016132A patent/BRPI1016132B8/pt active IP Right Grant
- 2010-03-31 EP EP10714386.9A patent/EP2413913B1/en active Active
- 2010-03-31 MX MX2011010311A patent/MX361618B/es active IP Right Grant
- 2010-03-31 DK DK10714386.9T patent/DK2413913T3/da active
- 2010-03-31 PT PT107143869T patent/PT2413913T/pt unknown
- 2010-03-31 CN CN201610184873.1A patent/CN105816456A/zh active Pending
- 2010-03-31 PL PL10714386.9T patent/PL2413913T3/pl unknown
-
2015
- 2015-08-27 JP JP2015168153A patent/JP6336420B2/ja active Active
-
2018
- 2018-09-05 US US16/122,643 patent/US20190008774A1/en not_active Abandoned
-
2020
- 2020-12-15 US US17/122,013 patent/US20210315824A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5864410B2 (ja) | 2016-02-17 |
| US20190008774A1 (en) | 2019-01-10 |
| WO2010114405A3 (en) | 2011-01-06 |
| BRPI1016132A2 (pt) | 2016-04-19 |
| US20210315824A1 (en) | 2021-10-14 |
| CN102438595B (zh) | 2016-04-27 |
| WO2010114405A2 (en) | 2010-10-07 |
| KR101824257B1 (ko) | 2018-01-31 |
| ES2915698T3 (es) | 2022-06-24 |
| JP2012522764A (ja) | 2012-09-27 |
| RU2550133C2 (ru) | 2015-05-10 |
| EP2413913B1 (en) | 2022-05-18 |
| RU2011143619A (ru) | 2013-05-10 |
| CN105816456A (zh) | 2016-08-03 |
| PL2413913T3 (pl) | 2022-09-26 |
| KR20120008040A (ko) | 2012-01-25 |
| AU2010231962A1 (en) | 2011-11-17 |
| MX361618B (es) | 2018-12-13 |
| US20100256194A1 (en) | 2010-10-07 |
| BRPI1016132B1 (pt) | 2020-11-24 |
| PT2413913T (pt) | 2022-06-09 |
| CA2757418A1 (en) | 2010-10-07 |
| JP2016020369A (ja) | 2016-02-04 |
| AU2010231962B2 (en) | 2015-05-21 |
| MX2011010311A (es) | 2012-03-07 |
| JP6336420B2 (ja) | 2018-06-06 |
| EP2413913A2 (en) | 2012-02-08 |
| DK2413913T3 (da) | 2022-06-13 |
| CN102438595A (zh) | 2012-05-02 |
| CA2757418C (en) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1016132B8 (pt) | composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável | |
| BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
| CY1121776T1 (el) | C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων | |
| MX2011010415A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
| MX2018000916A (es) | Derivados de benzodiazepina como inhibidores de rsv. | |
| BR112014009146A2 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
| BRPI1011657A2 (pt) | derivados aminopropiônicos substituídos como inibidores de neprilisina | |
| IN2015DN01547A (enExample) | ||
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
| BR112013006936A2 (pt) | composto de amida substituída | |
| BR112015014753A2 (pt) | composições, utilização de uma composição, método para o combate dos fungos fitopatogênicos e semente | |
| TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
| CU20110207A7 (es) | Aril piridinas como inhibidoras de sintasa de aldosterona | |
| CY1115043T1 (el) | Φαρμακευτικο σκευασμα | |
| EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
| BR112012011328A2 (pt) | inibidores de akt | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| PH12015501752B1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| MY196788A (en) | Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof | |
| DOP2014000265A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| ECSP11011048A (es) | Inhibidores de cinasa akt y p70 s6 | |
| BR112013023266B8 (pt) | inibidores da girase tricíclicos | |
| CO6361855A2 (es) | Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos | |
| NZ708821A (en) | Lfa-1 inhibitor formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |